RIPK1 and amyotrophic lateral sclerosis: The result showed that the serum levels of RIPK1 and IL-8 in the ALS patients treated with primidone at the dosage of 31.25 mg/day were significantly reduced compared with their initial levels at baseline (Supplementary Fig. 3).